Search Results - "Keystone EC"

Community poverty level influences time to first pediatric rheumatology appointment in Polyarticular Juvenile Idiopathic Arthritis.

Authors: Balmuri, Nayimisha Soulsby, William Daniel Cooley, Victoria et al.

Source: Pediatric Rheumatology. 8/14/2021, Vol. 19 Issue 1, p1-9. 9p.

A phase I open label study of fostamatinib, a SYK inhibitor, in patients with lower-risk myelodysplastic syndrome and chronic myelomonocytic leukemia.

Authors: Croden, J. Garcia-Manero, G. Chien, K. et al.

Source: Leukemia & Lymphoma. Jun2026, Vol. 67 Issue 7, p1580-1586. 7p.

Serious Infection Risk with Systemic Treatments for Psoriasis: A Systematic Review and Network Meta-analysis Combining Randomised and Non-randomised Evidence.

Authors: Bright, Heber Rew Bright Phan, Duc Binh Zahid, Amna et al.

Source: Dermatology & Therapy. Jan2026, Vol. 16 Issue 1, p191-204. 14p.

Rituximab-associated hypogammaglobulinemia in children with idiopathic nephrotic syndrome: results of an ESPN survey.

Authors: Zurowska, Aleksandra Drozynska-Duklas, Magdalena Topaloglu, Rezan et al.

Source: Pediatric Nephrology. Sep2023, Vol. 38 Issue 9, p3035-3042. 8p. 3 Charts, 2 Graphs.

Author acknowledgement 2020.

Source: Scandinavian Journal of Rheumatology. Nov2020, Vol. 49 Issue 6, p516-518. 3p.

Mycobacterium tuberculosis impairs protective cytokine production via transcription factor MafB manipulation.

Authors: Saiga, Hiroyuki Ueno, Masaki Tamura, Toshiki et al.

Source: PLoS Pathogens. 9/4/2025, Vol. 21 Issue 9, p1-21. 21p.

Oral glucocorticoid premedication for preventing infusion-related reactions to rituximab in rheumatoid arthritis.

Authors: Bovens, PMET van Esveld, L Wientjes, MHM et al.

Source: Scandinavian Journal of Rheumatology. May2026, Vol. 55 Issue 3, p172-176. 5p.

Positioning filgotinib in the therapeutic landscape of rheumatoid arthritis - alternative or complementary?

Alternate Title: Filgotinibin romatoid artrit tedavisindeki konumu - alternatif mi, tamamlayıcı mı?

Authors: Menemencioğlu, Rukiye Şahinbaş, Burcu Altun, Ahmet

Source: Journal of Turkish Society for Rheumatology. 2026, Vol. 18 Issue 2, p122-129. 8p.

Effectiveness and Safety of Tofacitinib Up to 36 Months in Canadian Patients with Rheumatoid Arthritis: Final Results from the CANTORAL Study.

Authors: Haraoui, Boulos Choquette, Denis Sciortino, Cristina et al.

Source: Rheumatology & Therapy. Jun2026, Vol. 13 Issue 3, p843-853. 11p.

Author Index.

Source: Value in Health. Nov2008, Vol. 11 Issue 6, pA669-A680. 11p.

Atypical nucleus pulposus migration and calcification: A specific radiographic sign for lumbar rheumatoid spondylitis.

Authors: Cui, Haocheng Wang, Jingming Wang, Lei et al.

Source: PLoS ONE. 6/6/2025, Vol. 20 Issue 6, p1-12. 12p.

Prescription Pattern and Safety of Biologics in Autoimmune Rheumatologic Diseases in Tertiary Care Hospital of Bihar.

Authors: Shakur, Adil Ali Kumar, Raj Ranjan, Raushan Kumar et al.

Source: Clinical Medicine Insights: Arthritis & Musculoskeletal Disorders. 5/18/2026, Vol. 19, p1-7. 7p.

ALSUntangled #67: rituximab.

Authors: Li, Xiaoyan Armon, Carmel Barkhaus, Paul et al.

Source: Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration. Aug2023, Vol. 24 Issue 5/6, p544-547. 4p.

Real‐world effectiveness and persistence of golimumab as second‐line anti‐TNFα drug in rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis patients in Italy: GO‐BEYOND, a 12‐month prospective observational study

Authors: D'Angelo, Salvatore Tirri, Enrico Giardino, Angela Maria et al.

Source: International Journal of Rheumatic Diseases. Mar2024, Vol. 27 Issue 3, p1-7. 7p.

Evaluation of pediatric rheumatologists' approach to rituximab use: a questionnaire study.

Authors: Sunar Yayla, Emine Nur Gezgin Yıldırım, Deniz Adıgüzel Dündar, Hatice et al.

Source: European Journal of Pediatrics. Sep2024, Vol. 183 Issue 9, p3959-3968. 10p.

Long-Term Effectiveness of Baricitinib and Other b/tsDMARDs in Patients with Rheumatoid Arthritis with Early Low Disease Activity or Remission: 2-Year Data from the RA-BE-REAL Study.

Authors: Alten, Rieke Östör, Andrew Edwards, Christopher J. et al.

Source: Rheumatology & Therapy. Feb2026, Vol. 13 Issue 1, p231-242. 12p.

Real-World Analysis of Initial Clinical Response and Future Outcomes Among Patients with Rheumatoid Arthritis Initiating and Remaining on a First-Line Tumor Necrosis Factor Inhibitor in the United States.

Authors: Charles-Schoeman, Christina Zueger, Patrick McDearmon-Blondell, Erin et al.

Source: Rheumatology & Therapy. Feb2026, Vol. 13 Issue 1, p95-114. 20p.

Efficacy, retention, and safety of baricitinib in real-life: HUR-BIO monocentric experience.

Alternate Title: Baricitinibin gerçek hayattaki etkinliği, kalıcılığı ve güvenliği: HÜR-BİO tek merkezli deneyimi.

Authors: Ekici, Mustafa İçli, İrem Yıldız Deregözü, Ece Ersal et al.

Source: Journal of Turkish Society for Rheumatology. 2026, Vol. 18 Issue 1, p108-118. 11p.

Intravenous Golimumab in the Treatment of Juvenile Idiopathic Arthritis and Its Associated Uveitis.

Authors: Khan, Shawn Saigal, Khushi Sheth, Sohum et al.

Source: Ocular Immunology & Inflammation. Dec2025, Vol. 33 Issue 10, p2245-2249. 5p.

Tuberculosis risk in patients with Crohn's disease on biologics: a retrospective analysis of the Japanese Medical Claims Database.

Authors: Fujimoto, Koji Hosomi, Shuhei Kobayashi, Yumie et al.

Source: Intestinal Research. Jul2025, Vol. 23 Issue 3, p309-317. 9p.